Ortho-McNeil Pharmaceutical, Inc. v. Lupin Pharmaceuticals, Inc., 603 F.3d 1377, CPLRG 0065 (Fed. Cir. 2010) (NEWMAN, Rader & Linn) OrthoLupin05102010

MAJOR ISSUES: patent term extension for drugs, Hatch-Waxman Act; first commercial marketing of “drug product”; active ingredient of drug product; enantiomer distinct from racemate Read CPLRG™ 0065

Photocure ASA v. Kappos, 603 F.3d 1372, 2010 U.S. App. LEXIS 9465 (Fed. Cir. 2010) (NEWMAN, Rader & Linn)Photocure05102010

MAJOR ISSUES: patent term extension for drugs, Hatch-Waxman Act; first commercial marketing of “drug product”; active ingredient of drug product; methyl ester of compound in previous drug Read CPLRG™ 0066

Robertson v. Timmermans, 603 F.3d 1309, CPLRG 0064 (Fed. Cir. 2010) (PLAGER, Linn & Dyk)Robertson05052010

MAJOR ISSUES: claim interpretation; construing claims copied from another patent or application to provoke an interference; written description requirement Read CPLRG™ 0064

Optium Corp. v. Emcore Corp., 603 F.3d 1313, CPLRG 0063 (Fed. Cir. 2010) (NEWMAN & Mayer; PROST, concurring in the result)OptiumEmcore05052010

MAJOR ISSUES:  inequitable conduct; intent to deceive the PTO; no presumption from high materiality and lack of credible explanation for nondisclosure Read CPLRG™ 0063

Rolls-Royce, PLC v. United Technologies Corp., 603 F.3d 1325, CPLRG 0062 (Fed. Cir. 2010) (RADER, Michel & Schall) RollsRoyaceUnitedTech05052010

MAJOR ISSUES:  obviousness; secondary considerations; commercial success; obvious to try; no motivation to combine; claim construction in PTO interference; broadest reasonable construction; unreasonable construction; interference-in-fact. Read CPLRG™ 0062